Australian University Rankings Guide

The International Journal of Chronic Obstructive Pulmonary Disease (ERA Journal)

The International Journal of Chronic Obstructive Pulmonary Disease is an ERA accredited research journal used as part of the evaluation of the ERA research rankings.

The International Journal of Chronic Obstructive Pulmonary Disease issns are issn1: 1176-9106 issn2: 1178-2005.

The field covered by The International Journal of Chronic Obstructive Pulmonary Disease as part of the evaluation of Australian university research excellence is:

Cardiorespiratory Medicine and Haematology Research Rankings (Sub-Field)

Other ERA-accredited journals supporting the evaluation of the Cardiorespiratory Medicine and Haematology field include:

- American Journal of Cardiovascular Drugs
- Angeiologie
- British Journal of Cardiology
- Clinical Cardiology (Hoboken): an indexed and peer-reviewed journal for advances in the treatment of cardiovascular disease
- Clinical and Applied Thrombosis / Hemostasis
- Current Opinion in Cardiology
- Current Opinion in Lipidology
- Indian Journal of Hematology and Blood Transfusion
- JACC: Cardiovascular Interventions
- Journal of Atherosclerosis and Thrombosis
- Nature Reviews Cardiology
- Open Cardiovascular Medicine Journal
- Sarcoidosis Vasculitis and Diffuse Lung Diseases
- The Journal of Heart Valve Disease
- Trends in Cardiovascular Medicine


ERA Research Rankings Submenu


- ERA 2018 Outcomes Research Rankings List

- ERA 2018 Research Rankings Analysis

- ERA 2018 Individual University Outcomes List

- ERA List of Research Fields Rankings

- ERA Journal Rankings 2018 List



Latest News and Updates:


- Top 10 Best Australian Universities

- Gender Balance Male-Female Ratio

- ERA 2018 Outcomes Research Rankings List

- University Bachelor Degree Completion Rates

- QS Employability Rankings Australian Universities

- ARWU World Rankings of Australian Universities

- Group of Eight (go8) World Rankings

Share This Page

  • Share on Facebook1
  • Share on Twitter2
  • Share on Linkedin3
  • Share on Reddit4